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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy of temozolomide in children and adolescents with newly diagnosed and progressive DIPG.
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B A C K G R O U N D
Description of the condition
Diffuse intrinsic pontine glioma (DIPG) is one of the most devas-
tating childhood cancers. The incidence is 0.1 per 100,000 chil-
dren per year and DIPG accounts for 7 percent of all pediatric
central nervous system tumors (Kaatsch 2001).DIPGusually con-
cerns high grade glioma (grade III or glioblastomamultiforme) but
can also be grade II diffuse astrocytoma (Fisher 2000); even primi-
tive neuroectodermal tumor (PNET) histology has been described
in occasional subjects (Zarghooni 2010). Diagnosis is based on
magnetic resonance imaging (MRI), which typically shows a dif-
fusely swollen pons and encasement of the basilary artery by the tu-
mor. Treatment is difficult because of the delicate location within
the pons from which the majority of the cranial nerves originate.
This makes radical surgery too dangerous (Epstein 1986). In addi-
tion, several anti-cancer drugs appeared to be inactive inDIPG, ei-
ther due to tumor drug resistance and/or poor drug distribution in
the tumor due to a frequently intact blood brain barrier (Hargrave
2006; Hargrave 2008). Radiotherapy can significantly reduce the
tumor and often improves clinical signs, but these effects are al-
most always temporary (Langmoen 1991). For these reasons, the
prognosis of DIPG has remained unchanged in the past 30 years
with a median overall survival rate of nine months and a two-
year overall survival rate of less than 10 percent ( Hargrave 2006;
Jansen 2012).
Description of the intervention
Temozolomide, an imidazotetrazine derivative of dacarbazine, is
an oral alkylating drug. Once temozolomide enters the systemic
circulation it is converted to its active compound, monomethyl
triazeno imidazole carboxamide (MTIC) (Stevens 1987).
Nowadays, the use of temozolomide in the treatment of pediatric
and adult glioma is widespread. This extensive use resulted from
the report of a phase III trial in 2005, in which temozolomide was
given concurrently with radiotherapy and as adjuvant treatment
for adult high grade glioma (Stupp 2005). Themedian overall sur-
vival increased from 12.1 to 14.6 months (P < 0.001) with temo-
zolomide compared to radiotherapy alone. This study resulted in
the approval of temozolomide for the treatment of newly diag-
nosed glioblastoma multiforme (GBM). These results were con-
firmed in a systematic review on temozolomide for high grade
glioma in 2008 (Hart 2008). In addition, temozolomide was also
approved for the treatment of refractory anaplastic astrocytoma.
In the mean time, phase I studies with temozolomide in children
were initiated. Temozolomide was found to be safe in children
with mainly hematological toxicity, which was comparable to that
been observed in adults (Estlin 1998).
Why it is important to do this review
After the successes obtained in adults, multiple temozolomide tri-
als were initiated in children and young adults with glioma, both
with conventional and protracted dose schedules (Baruchel 2006;
Broniscer 2006; Cohen 2011b; Jakacki 2008; Lashford 2002;
Nicholson 2007; Ruggiero 2006; Verschuur 2004). This also ap-
plies to DIPG, where multiple studies were published from 2005
with temozolomide alone or in combination with other drugs
(Broniscer 2005; Chassot 2012; Cohen 2011a; Jalali 2009; Kim
2010; Sharp 2010; Sirachainan 2008). Furthermore, temozolo-
mide became a drug that was frequently prescribed off protocol
to patients with DIPG. However, the efficacy of temozolomide in
children with DIPG is unclear. To the best of our knowledge, no
systematic review has been done on temozolomide in children and
adolescents with DIPG thus far. The results from this systematic
review thus answer the clinical question whether children and ado-
lescents with DIPG should or should not be treated with temo-
zolomide and to identify subgroups of patients who may benefit
from temozolomide treatment.
O B J E C T I V E S
To assess the efficacy of temozolomide in children and adolescents
with newly diagnosed and progressive DIPG.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs), clinically
controlled trials (CCTs), unrandomized single-arm trials with his-
torical controls and cohort studies examining the efficacy of temo-
zolomide in the treatment of childhood and adolescent DIPG.
Cross-sectional studies, case-reports and case series (i.e. a series
of non-consecutive patients) will be excluded. A cohort study is
defined as a study in which a group of consecutive patients treated
for DIPG was followed either from diagnosis or from time of pro-
gression onwards. The described study could be the original co-
hort or a subgroup of the original cohort based on well-defined
inclusion criteria. Studies including less than five patients will be
excluded.
Types of participants
Patients aged < 21 years with clinical and MRI features consistent
with the diagnosis of diffuse intrinsic pontine glioma are eligible.
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Patients can be either newly diagnosed with no prior therapy other
than corticosteroids or with disease progression after radiotherapy.
The MRI criteria include a T1 iso- or hypointense, T2 hyperin-
tense tumor originating in the pons, with at least 50% involve-
ment of the pontine region. Patients diagnosed by computed to-
mography (CT) only will be excluded, since CT is not sensitive
for diagnosing pontine glioma (Packer 1985). Histological con-
firmation by means of biopsy is not mandatory. In cases where
pathologic analysis of the tumor is available, histological diagnosis
should be grade 2-4 astrocytoma or grade 2-3 oligodendroglioma
or oligoastrocytoma, located in the pons (Fisher 2000). We will
exclude exophytic tumors and cases of pilocytic astrocytomas and
primitive neuroectodermal tumors (PNET) of the brainstem. If
studies include both eligible and non-eligible patients, the results
of only eligible patients should be available for inclusion in the
review.
Types of interventions
Treatment with temozolomide, either neo-adjuvant, concomitant
or adjuvant to fractionated radiotherapy. Both treatment arms of
the RCTorCCTor, in case the control group is a historical cohort,
both the current and historical cohort, should receive fractionated
radiotherapy. Treatment protocols are allowed to include support-
ive care, e.g. glucocorticosteroids, anti-epileptics and other drugs
depending on appropriate clinical need, as well as additional anti-
cancer drugs in the treatment regimen.
Types of outcome measures
Primary outcomes
Newly diagnosed patients
• Overall survival, defined as the interval between tumor
diagnosis and death from any cause.
Patients with progressive disease
• Radiological response rate, defined as the total number of
patients with a complete or partial response. Response criteria as
assessed by MRI according to definitions of the authors of the
original study.
Secondary outcomes
Newly diagnosed patients
• Progression free survival, defined as the interval between
tumor diagnosis and clinical and/or radiological tumor
progression or death
• Radiological response evaluation, defined as the total
number of patients with a complete or partial response.
Response criteria as assessed by MRI according to definitions of
the authors of the original study
Patients with progressive disease
• Overall survival defined as the interval between start of
temozolomide treatment and death
• Progression free survival defined as the interval between
start of temozolomide treatment and clinical and/or radiological
tumor progression or death
Both groups
• Clinical response in terms of reduction in signs or
symptoms(endpoint: total number of clinical responses)
• Adverse events as defined by the authors of the original
study
• Performance score based on Karnofsky 1949 or Lansky
1987
Search methods for identification of studies
We will use the Cochrane Childhood Cancer Group search meth-
ods (Kremer 2011). We will not impose language restrictions.
Searches will be updated every two years.
Electronic searches
We will search the following electronic databases: the Cochrane
Central Register of Controlled Trials (CENTRAL) in The
Cochrane Library (latest issue), MEDLINE (PubMed; from 1945
to present) and EMBASE (Ovid; from 1980 to present).
The search strategies for the different electronic databases (using a
combination of controlled vocabulary and text words) are shown
in the appendices (Appendix 1; Appendix 2; Appendix 3)
Searching other resources
We will locate information on trials not registered in MEDLINE,
EMBASE or CENTRAL, either published or unpublished, by
searching the reference lists of relevant articles and review arti-
cles. We will handsearch the conference proceedings of the In-
ternational Society for Paediatric Oncology (SIOP), the Society
for Pediatric Neuro-Oncology (SPNO), the Society for Neuro-
Oncology (SNO), the American Association for Cancer Research
(AACR), the American Society of Clinical Oncology (ASCO),
the European Association for Cancer Research (EACR), and the
European Association for Neuro-Oncology (EANO) published
between 2006 and 2011. We will scan the World Health Orga-
nization International Clinical Trials Registry Platform (ICTRP)
search portal (http://apps.who.int/trialsearch/), the International
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Standard Randomised Controlled Trial Number Register (IS-
RCTN Register) (http://www.controlled-trials.com/isrctn/) and
ClinicalTrials.gov (http://clinicaltrials.gov/) for ongoing trials.
Data collection and analysis
Selection of studies
After performing the search strategy described previously, two au-
thors (MJ, SV) will independently select studies meeting the in-
clusion criteria. All discrepancies between the two authors will be
resolved by consensus. Otherwise, final resolution will be achieved
by using a third-party arbitrator (DvV, GJK, EVD). We will ob-
tain in full any study which seems to meet the inclusion criteria on
grounds of the title and/or abstract for closer inspection. We will
clearly state details of reasons for exclusion of any study considered
for this review.
Data extraction and management
Two authors (MJ, SV) will independently perform data extraction
using standardized forms. Discrepancies between authors will be
resolved by discussion. If this is impossible, we will achieve final
resolution using a third-party arbitrator (DvV, GJK, EVD).
Data will be extracted on the following items:
1. Study characteristics
• Design
• Number of patients enrolled in the study
• Number of patients fulfilling the authors’ inclusion criteria
2. Participants characteristics
• Sex
• Age at time of diagnosis
• Duration of symptoms at diagnosis
• MRI characteristics
• Stage of disease
• Biopsy for histology and O6-methylguanine-DNA
methyltransferase (MGMT) promoter methylation status
• Neurofibromatosis status
3. Interventions
• Cumulative radiation dose (Gy) and number of fractions
• Temozolomide treatment protocol (dose and schedule)
• Neo-adjuvant, concomitant and/or adjuvant scheme
• Additive therapeutics (dose and schedule)
4. Outcome measures
• Overall survival (months)
• Progression free survival (months)
• Radiological response evaluation
• Clinical response
• Adverse events
• Performance scores
5. Length of follow-up
Assessment of risk of bias in included studies
Two review authors will independently perform the assessment of
risk of bias of the included studies (MJ and SV). For RCTs and
CCTs we will use the risk of bias items as described in the module
of the Childhood Cancer Group (Kremer 2011), which are based
on the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). The assessment of risk of bias in observational
studies will be based on previously described checklists according
to Evidence-Based Medicine Criteria (Grimes 2002; Laupacis
1994). See Table 1 for the definitions of the different risk of bias
criteria. The risk of bias in included studies will be taken into
account in the interpretation of the review’s results.We will resolve
discrepancies between authors by consensus. If this is not possible,
wewill achieve final resolution using a third-party arbitrator (DvV,
GJK, EVD).
Measures of treatment effect
If a control group is available, dichotomous variables will be an-
alyzed using risk ratios (RRs); continuous outcomes will be ana-
lyzed using mean differences (MDs), survival will be analyzed us-
ing hazard ratios (HRs). We will use Parmar’s method if HRs were
not explicitly presented in the study (Parmar 1998). If no con-
trol group is available, we will use the prevalence to analyze radi-
ological response and adverse effects; survival will be summarized
descriptively. All results will be presented with the corresponding
95% confidence intervals (CIs).
Dealing with missing data
When relevant data regarding study selection, data extraction and
risk of bias assessment are missing, we will attempt to contact
the study authors to retrieve the missing data. We will extract
data by the allocated intervention, irrespective of compliance with
the allocated intervention, in order to allow an intention-to-treat
analysis. If this is not possible, this will be stated and we will
perform a per-protocol analysis.
Assessment of heterogeneity
We will assess heterogeneity both by visual inspection of the for-
est plots and by a formal statistical test for heterogeneity, the I
2 statistic. In the absence of significant heterogeneity (I2 < 50%)
(Higgins 2011), we will use a fixed-effect model for the estimation
of treatment effects. Otherwise, we will explore possible reasons
for the occurrence of heterogeneity and take appropriate measures.
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Assessment of reporting biases
In addition to the evaluation of reporting bias as described in
the ’Assessment of risk of bias in included studies’ section, we
will assess reporting bias by constructing a funnel plot if at least
10 studies are included in a meta-analysis. When there are fewer
studies the power of the tests is too low to distinguish chance from
real asymmetry (Higgins 2011).
Data synthesis
We will enter data into the Cochrane Collaboration’s statistical
software, Review Manager (Review Manager 2011), and under-
take analyses according to the guidelines of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
will include outcome measures only if it was the intention of the
study to perform the necessary assessments in all patients (that
is, not only optional or only performed in some centers). Newly
diagnosed patients and patients with progressive disease will be
analyzed separately. We will pool results only if studies are compa-
rable with regard to important prognostic factors (e.g. percentage
of pontine tumor infiltration, time between onset of symptoms
and diagnosis and age at diagnosis) and used outcome definitions.
Different study designs will be taken into account in the analyses.
Studies for which pooling of results is not possible will be sum-
marized descriptively.
Subgroup analysis and investigation of heterogeneity
The following variables may influence prognosis:
• newly diagnosed versus progressive DIPG;
• age ≥ three years versus < three years at time of diagnosis:
younger age correlates with a better prognosis (Broniscer 2008);
• time between onset of symptoms (more or less than six
months) and diagnosis: shorter duration of symptoms may reflect
more aggressive tumors with a worse prognosis (Ueoka 2009)
• histology: low grade versus high grade glioma; the latter
may reflect a slightly worse prognosis (Wagner 2006);
• neurofibromatosis type 1 (NF-1): an increased survival
among DIPG patients considered to have NF-1 has been
reported (Milstein 1989);
• percentage of pontine infiltration by the tumor;
• enhancement on MRI at diagnosis or enhancement that
correlates with a worse overall survival (Poussaint 2011);
• O6-methylguanine-DNA methyltransferase (MGMT)
promoter methylation status of the tumor; MGMT methylation
correlates with an increased response to temozolomide (Hegi
2005); and
• additional, second- or third-line therapeutics.
Sensitivity analysis
For all outcomes for which pooling is possible we will perform
sensitivity analyses for all risk of bias criteria separately. We will
exclude studies of high risk of bias and studies for which the risk
of bias is unclear and compare the results of studies with a low risk
of bias with the results of all available studies.
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A D D I T I O N A L T A B L E S
Table 1. Risk of bias criteria for observational studies
Internal validity External validity
Study group Selection bias (representative: yes/no):
• If the described study group consisted of more than
90% of the DIPG patients treated with temozolomide
included in the original cohort
• Or if it was a random sample of these patients with
respect to important prognostic factors (like percentage
of pontine tumor infiltration, time between onset of
symptoms and diagnosis and age at diagnosis) and
cancer treatment
Reporting bias (well defined: yes/no):
• If the mean, median or range of the cumulative
temozolomide dose was mentioned
• And when it was described what other treatment
(including the received doses) was given
• And when the MRI criteria used for tumor
diagnosis were mentioned
• And when the mean, median or range of the
patients age was mentioned
Follow-up Attrition bias (adequate: yes/no):
• If the outcome was assessed for more than 90% of
the study group of interest (++)
• Or if the outcome was assessed for 60-90% of the
study group of interest (+)
Reporting bias (well-defined: yes/no):
• If the length of follow-up was mentioned
Outcome Detection bias (blind: yes/no):
• If the outcome assessors were blinded to the
investigated determinant
Reporting bias (well-defined: yes/no):
• If the outcome definition was provided
DIPG: diffuse intrinsic pontine glioma
A P P E N D I C E S
Appendix 1. Search strategy for CENTRAL (The Cochrane Library)
1. For Temolozomide the following text words will be used:
Temolozomide OR 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one OR methazolastone OR MB 39831 OR MB-
39831 OR Temodar OR Temodal OR Schering-Plough brand of temozolomide OR Essex brand of temozolomide OR Schering brand
of temozolomide OR TMZ-Bioshuttle OR CCRG 81045 OR CCRG-81045 OR NSC 362856 OR NSC-362856 OR 85622-93-1
2. For Gliomas the following text words will be used:
diffuse intrinsic pontine glioma OR diffuse intrinsic pontine gliomas OR diffuse intrinsic pontine gliom* OR DIPG OR pontine
gliom* OR diffuse pontine gliom* OR brainstem gliom* OR brain stem gliom* OR brainstem tumor* OR brainstem tumour* OR
brain stem tumor* OR brain stem tumour* OR high grade glioma OR high grade gliomas OR high grade gliom* OR glioblastoma
multiformeOR glioblastoma OR glioblastom*OR anaplastic astrocytomaORfibrillary astrocytomaORGBMORdiffuse astrocytoma
OR diffuse fibrillary astrocytoma OR astrocytom*
3. For Chilldren and adolescents the following text words will be used:
infan* OR newborn* OR new-born* OR perinat* OR neonat* OR baby OR baby* OR babies OR toddler* OR minors OR minors*
OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child OR child* OR children* OR schoolchild* OR
schoolchild OR school child[tiab] OR school child*[tiab] OR adolescen* OR juvenil* OR youth* OR teen* OR under*age* OR
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pubescen* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR school OR school* OR prematur* OR preterm* OR
“young adult” OR “young adults”
Final search 1 AND 2 AND 3
The search will be performed in title, abstract or keywords
[*=zero or more characters]
Appendix 2. Search strategy for MEDLINE (PubMed)
1. For Temolozomide the following MeSH headings and text words will be used:
Temolozomide OR 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one OR methazolastone OR MB 39831 OR MB-
39831 OR Temodar OR Temodal OR Schering-Plough brand of temozolomide OR Essex brand of temozolomide OR Schering brand
of temozolomide OR TMZ-Bioshuttle OR CCRG 81045 OR CCRG-81045 OR NSC 362856 OR NSC-362856 OR 85622-93-1
2. For Gliomas the following MeSH headings and text words will be used:
diffuse intrinsic pontine glioma OR diffuse intrinsic pontine gliomas OR diffuse intrinsic pontine gliom* OR DIPG OR pontine
gliom* OR diffuse pontine gliom* OR brainstem gliom* OR brain stem gliom* OR brainstem tumor* OR brainstem tumour* OR
brain stem tumor* OR brain stem tumour* OR high grade glioma OR high grade gliomas OR high grade gliom* OR glioblastoma
multiformeOR glioblastoma OR glioblastom*OR anaplastic astrocytomaORfibrillary astrocytomaORGBMORdiffuse astrocytoma
OR diffuse fibrillary astrocytoma OR astrocytom*
3. For Children and adolescents the following MeSH headings and text words will be used:
infan* OR newborn* OR new-born* OR perinat* OR neonat* OR baby OR baby* OR babies OR toddler* OR minors OR minors*
OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child OR child* OR children* OR schoolchild* OR
schoolchild OR school child[tiab] OR school child*[tiab] OR adolescen* OR juvenil* OR youth* OR teen* OR under*age* OR
pubescen* OR pediatrics[mh] OR pediatric* OR paediatric* OR peadiatric* OR school[tiab] OR school*[tiab] OR prematur* OR
preterm* OR “young adult” OR “young adults” OR young adult[mh]
Final search 1 AND 2 AND 3
[tiab = title, abstract; mh = MeSH term; *=zero or more characters]
Appendix 3. Search strategy for EMBASE (Ovid)
1. For Temolozomide the following Emtree terms and text words will be used:
1. exp temozolomide/
2. temolozomide.mp.
3. (methazolastone or MB 39831 or MB-39831 or Temodar or Temodal).mp.
4. (TMZ-Bioshuttle or CCRG 81045 or CCRG-81045 or NSC 362856 or NSC-362856).mp.
5. 85622-93-1.rn.
6. or/1-5
2. For Gliomas the following Emtree terms and text words will be used:
1. exp pontine glioma/
2. (diffuse intrinsic pontine glioma or diffuse intrinsic pontine gliomas or diffuse intrinsic pontine gliom$).mp.
3. (DIPG or pontine gliom$ or diffuse pontine gliom$).mp.
4. (brainstem gliom$ or brain stem gliom$).mp.
5. (brainstem tumor$ or brainstem tumour$ or brain stem tumor$ or brain stem tumour$).mp.
6. (high grade glioma or high grade gliomas or high grade glioma$).mp.
7. exp glioblastoma/
8. (glioblastoma multiforme or glioblastoma or glioblastom$).mp.
9. anaplastic astrocytoma.mp.
10. exp astrocytoma/
11. (fibrillary astrocytoma or GBM or diffuse astrocytoma or diffuse fibrillary astrocytoma or astrocytom$).mp.
12. or/1-11
3. For Children and adolescents the following Emtree terms and text words will be used:
1. infan$.mp.
2. (newborn$ or new-born$).mp.
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3. (perinat$ or neonat$).mp.
4. baby/
5. (baby or baby$ or babies).mp.
6. toddler$.mp.
7. (minors or minors$).mp.
8. (boy or boys or boyfriend or boyhood).mp.
9. girl$.mp.
10. (kid or kids).mp.
11. child/
12. (child or child$ or children$).mp.
13. school child/
14. (schoolchild$ or schoolchild).mp.
15. (school child or school child$).ti,ab.
16. (adolescen$ or youth$ or teen$).mp.
17. (juvenil$ or under$age$).mp.
18. pubescen$.mp.
19. exp pediatrics/
20. (pediatric$ or paediatric$ or peadiatric$).mp.
21. (school or school$).mp.
22. (prematur$ or preterm$).mp.
23. (young adult or young adults or young adult$).mp.
24. or/1-23
Final search: 1 and 2 and 3
[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name;
ti,ab = title, abstract; / = Emtree term; $=zero or more characters; rn=CAS registry number]
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• Egbers Foundation, Netherlands.
11Temozolomide for children and adolescents with diffuse intrinsic pontine glioma (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
